Should the FDA require biosimilar medications to have a unique International Nonproprietary Name (INN) from brand-name biologics?
Yes: 25%
No: 75%
September 2026 Question of the Month Results
October 1, 2026
October Question of the Month
Stay Up to Date
October Question of the Month
Recent Posts
Drug Shortages Are Improving, but Supply Chain Bottlenecks Remain a Threat
September 15, 2026
August 2026 Question of the Month Results
September 2, 2026